Recent Updates
Recently added Catalysts
OCS Neutral Sentiment

Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities

Friday, September 26, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Oculis has published a notification regarding transactions by a Person Discharging Managerial Responsibilities (PDMR) in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The notification pertains to trades executed under a trading plan by a PDMR, indicating standard compliance with regulatory requirements. This information is essential for investors monitoring insider trading activities.
Price reaction · baseline $17.5 (2025-09-25 close) · hit after-hours · clean, no other OCS news in the window
day 0 close · peak
+0.7%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
3.8%
average across 4 past catalysts
Lead asset
Privosegtor
Phase 3 · Optic Neuritis

Full Press Release Details

ZUG, Switzerland, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended.
pdmr-notification-r-sherif-sales-sep 2025

Frequently Asked Questions

What is the purpose of the notification?

The notification pertains to trades made by a PDMR under a 10b5-1 trading plan.

Which trading rule applies to this notification?

This notification follows Rule 10b5-1(c)(1) of the Securities Exchange Act.

When was the notification released?

The notification was released on September 26, 2025.

Where was the notification published?

The notification was published in Zug, Switzerland.

ShareAdd on Google
Tags: OCS Viatris Investor Conferences Healthcare Oculis PDMR trading plan Securities Exchange Act Switzerland
Last updated: Sep 26, 2025

Biotech snapshot

Lead asset
PrivosegtorPhase 3
Optic Neuritis →

Catalyst track record

+32%
best trade around OCS's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for OCS.

See every catalyst's timing & PoA →